NSE: NATCOPHARM | BSE: 524816

Mid-range Performer

Download real time

905.65 -11.90 (-1.30%)

39.22% Fall from 52W High

1.5M NSE+BSE Volume

NSE 12 Dec, 2025 3:31 PM (IST)

16,221.1

Market Cap

High in industry

Beta 1Year

Very High Volatility

Natco Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for NATCOPHARM, BSE:524816 Natco Pharma Ltd.

Natco Pharma Ltd.

27 Mar 2024

905.65

-1.30%

NATCO PHARMA

Accumulate: Natco Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Natco Pharma Ltd.

21 Feb 2024

905.65

-1.30%

Pick of the Day (Short Term Delivery Call)

Accumulate: Natco Pharma Ltd.

SBI Securities

Natco Pharma is a well-established player in the domestic formulations market with a significant market share in the domestic oncology segment. In oncology, it has brands catering to diseases including breast, bone, lung and ovarian cancer.

Natco Pharma has lost -38.41% in the last 1 Year

Natco Pharma Ltd.

11 Aug 2023

905.65

-1.30%

Traction across verticals

Hold: Natco Pharma Ltd.

Target

ICICI Securities Limited

Natco’s Q1FY24 performance was ahead of our expectations on all fronts. gRevlimid continues to be an important growth driver though, in Q1, domestic and agrochemical biz too picked up after a long haul. Windfall from gRevlimid is invested in R&D (8-10% of sales) to build a generic pharma and agrochemical pipeline to aid growth beyond gRevlimid.

Natco Pharma has lost -38.41% in the last 1 Year

Natco Pharma Ltd.

21 Jun 2023

905.65

-1.30%

NATCO PHARMA

Buy: Natco Pharma Ltd.

Target

Geojit BNP Paribas

Natco Pharma has lost -38.41% in the last 1 Year

Natco Pharma Ltd.

31 May 2023

905.65

-1.30%

R&D investments picking up

Hold: Natco Pharma Ltd.

Recommendation Target

ICICI Securities Limited

Natco Pharma’s (Natco) Q4FY23 revenue growth of 50% and margins were driven by higher sales in the export market. Company is confident of gaining further traction in the export business in the next couple of quarters.

Natco Pharma has lost -38.41% in the last 1 Year

Natco Pharma Ltd.

15 Feb 2023

905.65

-1.30%

Natco Pharma

Hold: Natco Pharma Ltd.

Target

ICICI Direct

Number of FII/FPI investors decreased from 317 to 235 in Sep 2025 qtr

Natco Pharma Ltd.

13 Feb 2023, 12:00AM

905.65

-1.30%

US drives growth

Buy: Natco Pharma Ltd.

ICICI Securities Limited

Natco Pharma’s (Natco) Q3FY23 performance was above our estimates on revenue front. Revenue grew 14% QoQ to Rs4.9bn (I-sec:4.7bn). YoY numbers are not comparable due to one-off licensing income in Q3FY22. US business saw a healthy sequential improvement driven by strong flu season sales.

Natco Pharma Ltd. has an average target of 845.00 from 2 brokers.

Natco Pharma Ltd.

05 Dec 2022

905.65

-1.30%

NATCO PHARMA

Buy: Natco Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

Number of MF schemes decreased from 47 to 19 in Sep 2025 qtr

Natco Pharma Ltd.

17 Nov 2022

905.65

-1.30%

Natco Pharma

Hold: Natco Pharma Ltd.

Target

ICICI Direct

Natco Pharma Ltd. is trading above all available SMAs

Natco Pharma Ltd.

14 Nov 2022

905.65

-1.30%

Stunted recovery mars performance

Buy: Natco Pharma Ltd.

Target

ICICI Securities Limited

Natco Pharma’s (Natco) Q2FY23 performance was lower than our estimates on all fronts. Revenue grew 14.6% YoY (-51.2% QoQ) to Rs4.3bn – below our expectation of
Rs5.6bn.

Natco Pharma Ltd. is trading above all available SMAs

Is Natco Pharma Ltd. worth buying?

594 Votes:

Buy 83.0%

Sell 7.41%

Hold 9.6%

RESEARCH REPORTS

Sell SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf